Bifosfonat Kullanımına Bağlı Maksilla ve Mandibulada Görülen Osteonekroz : Olgu Sunumu
Öz
Kaynakça
- Eid A, Atlas J. The role of bisphosphonates in medical oncology and their association with jaw bone necrosis. Oral Maxillofac Surg Clin North Am. 2014; 26: 231-7.
- Keleş E, Kaplama ME, Çobanoğlu B, Orhan İ. Bifosfonat Kullanımına Bağlı Maksillada Osteonekroz: Olgu Sunumu. Fırat Tıp Dergisi; 2011: 16: 160-3.
- DE Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, et al. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Res. 2014; 34: 2477-80.
- Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine. 2007; 74: 39-47.
- Woo SK, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Inter Med. 2006; 144: 753-61.
- Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83-93.
- Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-75.
- Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al. Bisphosphonate-Induced Osteonecrosis of the Jaws, Bone markers, and a Hypothesized Candidate Gene. J Oral Maxillofac Surg. 2009; 67: 159-161.
- Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws – clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol. 2010; 186: 367-73.
- Soydan SS, Şenel F, Araz K. Bifosfonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteonekrozun Patogenezi ve Tedavisi. Hacettepe Diş Hekimliği Fakültesi Dergisi. 2009; 33: 61-8.